Indications And Dose
Advanced prostate cancer | Metastatic prostate cancer refractory to gonadorelin analogue therapy (monotherapy) ▶BY MOUTH ▶Adult: 250 mg 3 times a day
PDF page 1022
Drug reference
Advanced prostate cancer | Metastatic prostate cancer refractory to gonadorelin analogue therapy (monotherapy) ▶BY MOUTH ▶Adult: 250 mg 3 times a day
PDF page 1022
Do not initiate if serum transaminases greater than 2–3 times the upper limit of normal
PDF page 1022
Avoid excessive alcohol consumption. avoid in Acute porphyrias p. 1120. cardiac disease (oedema reported). diabetes (decreased tolerance to glucose)
PDF page 1022
▶Common or very common Appetite abnormal. asthenia. breast abnormalities. diarrhoea. drowsiness. galactorrhoea. gynaecomastia. hepatic function abnormal (sometimes fatal). hepatitis (sometimes fatal). insomnia. nausea. vomiting ▶Rare or very rare Alopecia. anxiety. breast neoplasm. cardiovascular disorder. chest pain. constipation. cough. depression. dizziness. dyspnoea. gastrointestinal discomfort. gastrointestinal disorders. hair growth abnormal. headache. herpes zoster. hot flush. hypertension. interstitial pneumonitis. libido decreased. lupus-like syndrome. lymphoedema. malaise. muscle cramps. oedema. photosensitivity reaction. skin reactions . thirst. vision blurred ▶Frequency not known QT interval prolongation
PDF page 1022
Manufacturer advises caution.
PDF page 1022
Manufacturer advises caution.
PDF page 1022
▶Manufacturer advises monitor liver function before starting treatment, monthly for the first 4 months, and thereafter as clinically indicated. ▶Manufacturer advises monitor bone mineral density before starting treatment, after 1 year of treatment, and thereafter as clinically indicated. ▶Manufacturer advises monitor for respiratory symptoms during the first few weeks of treatment (interstitial pneumonitis reported).
PDF page 1022
There can be variation in the licensing of different medicines containing the same drug. Tablet ▶Flutamide (Non-proprietary) Flutamide 250 mg Flutamide 250mg tablets | 84 tablet P £106.23 DT = £106.23 OESTROGENS
PDF page 1022
Manufacturer advises patients and their carers should be told to discontinue treatment and seek immediate medical attention if signs or symptoms of hepatic toxicity occur.
PDF page 1022
250 mg 3 times a day
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1022